![Loading Events](https://facultydevelopment.mgh.harvard.edu/wp-content/plugins/the-events-calendar/src/resources/images/tribe-loading.gif)
- This event has passed.
Clinical Trial Office Fees for Industry-Sponsored Clinical Trials
July 1
Clinical Trial Office Fees for Industry-Sponsored Clinical Trials
Effective July 1, 2024
As a result of increases in external costs and for the first time since 2015, a global change in clinical trial office fees for industry-sponsored clinical trials will be instituted:
Current Fees:
Initial Fee: $5,000
Amendment Fee: $1,000
Sub-contract Fee: No charge for the first 4 agreements; $1,500 per agreement thereafter
New Fees as of July 1, 2024
Initial Fee: $6,500
Amendment Fee: $2,000
Sub-contract Fee: No change
New Exception:
CTO Fees will not be assessed on PI-initiated studies with a budget of $100,000 or less (inclusive of overhead).
Guidelines:
Increases apply to all new Insight records agreements accepted by the CTO on or after 7/1/24. Agreements accepted prior to 7/1/24 will be grandfathered into previous rates.
CTO Fees are applicable to projects that meet the following conditions:
- The CTO executes the agreement and/or approves the budget
- The agreement is eligible for the IDC rate of 35%
- The agreement has monetary funding. Agreements with travel reimbursement only are not charged the fee.
Agreement types where the fees are applied include, but are not limited to:
- Clinical Trial Agreements
- Clinical Research Support Agreements, including, but not limited to, agreements addressing activities for:
- Steering Committees
- Core Labs
- Data Monitoring Committees
- Coordinating Centers
- Executive Committee Membership
- Study Chair
- Study Protocol Development
- Institutional Consulting Agreements